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Abstract
Objective: The objective of this study was to define the clinical characteristics of osteonecrosis of the jaws (ONJ) 
induced by oral bisphosphonates in a series of patients from a circumscribed area in northwest Spain.
Study Design:A retrospective multicentre study was undertaken in 3 hospitals in an area with a radius less than 100 
km in the Autonomous Community of Galicia (Spain). The medical records were reviewed and an oral examination 
was performed of patients diagnosed with oral bisphosphonate-related ONJ in the previous 3 years. 
Results: �e detected 20 cases of ONJ (24 lesions) related to oral bisphosphonates (alendronate �1� patients� and iban-
dronate �4 patients�), which were mainly administered as treatment for osteoporosis (17 patients). The mean interval 
between initiation of treatment and confirmation of a diagnosis of ONJ was 66±43 months (range, 6-132 months); in 
7 patients (35%) the interval was less than 3� months. The past history revealed hypertension in 13 cases (�5%) and 
diabetes in 4 (20%); 7 patients (35%) were on corticosteroid treatment. Oral surgery had been previously performed 
in 13 patients (�5%) and the remaining 7 patients (35%) had removable dental prostheses. The lesions most frequently 
affected the posterior mandible (62.5%). The majority of the lesions (75%) were classified as stage 2, although lesions 
were identified in all established clinical stages (including 2 stage 0 lesions).
Conclusion: In conclusion, in the present series, ONJ induced by oral bisphosphonates typically develops in women 
around 70 years of age, taking alendronate, that underwent oral surgery. Most lesions are located in the posterior 
mandible and are classified as stage 2 at diagnosis. Some patients presented no known risk factors, suggesting that 
there may be risk factors still to be identified. There are well-defined patterns of clinical presentation that can facili-
tate early diagnosis of ONJ.
Key Wors: Oral bisphosphonates; osteonecrosis of the jaws; alendronate.
Med Oral Patol Oral Cir Bucal. 2012 Sep 1;17 (5):e751-8.                                                                                                                                      Osteonecrosis of the jaws and oral bisphosphonates
e752
Introduction
Osteoporosis is the most common metabolic bone disease 
and affects more than 200 million individuals worldwide 
(1); in Spain alone it affects more than 3 million individuals. 
As a result, there has been a progressive increase in recent 
years in the prescription of drugs to combat the disease, 
particularly oral bisphosphonates (2). The oral bisphospho-
nates most widely used for the treatment of osteopenia and 
osteoporosis are alendronate, risedronate, and ibandronate 
(3). Their efficacy derives mainly from their ability to in-
hibit bone resorption, which results in a significant reduc-
tion in the prevalence of vertebral and nonvertebral frac-
tures in postmenopausal women with osteoporosis. 
New adverse effects of the prolonged administration of bi-
sphosphonates have been detected in recent years; one of 
these, particularly important due to its associated morbid-
ity, is osteonecrosis of the jaws (ONJ). This is defined as 
an area of persistent bone exposure in patients treated with 
bisphosphonates but who have not received radiotherapy 
(4). The relationship between intravenous bisphosphonates 
and ONJ is based on firm epidemiological evidence, how-
ever, ONJ attributable to the use of oral bisphosphonates 
has been a subject of considerable controversy, although 
recent studies have provided evidence of this association 
(5). As patients with osteoporosis require prolonged treat-
ment, there has been an increase in the number of cases of 
ONJ related to the use of oral bisphosphonates, and in a 
recently published retrospective multicentre study it was 
suggested that the relative frequency of ONJ in patients 
with osteoporosis treated with oral bisphosphonates was 
higher than previously estimated (�).
The objective of this study was to define the clinical 
characteristics of a series of patients with ONJ induced 
by oral bisphosphonates in a circumscribed area in 
northwest Spain.
Material and Methods
A retrospective multicentre study was undertaken in 3 
hospitals in an area of less than 100 km in radius in the 
Autonomous Community of Galicia (Spain): Santiago 
de Compostela University Hospital Complex (CHUS), 
A Coruña University Hospital Complex (CHUAC), and 
Policlínico Vigo S.A. (POVISA) in Vigo. �e reviewed the 
medical records of all patients who had been diagnosed 
with ONJ related to the use of oral bisphosphonates during 
the period from May 2008 through April 2011 in any of 
the 3 involved hospitals. The inclusion criteria were those 
established by the American Association of Oral and Max-
illofacial Surgeons for the diagnosis of bisphosphonate-re-
lated ONJ (4): bone exposure in the maxillofacial region 
that persists for more than 8 weeks in patients treated with 
bisphosphonates (currently or previously) and who have 
not received radiation therapy to that anatomical region. In 
2009 these directives were updated to include patients with 
stage 0 disease (7). Other possible causes of ONJ were 
excluded on the basis of the medical history and, when 
necessary, additional tests (panoramic radiographs, 
computed tomography, histopathology examination, 
and microbiology cultures) were performed in order to 
establish the definitive diagnosis. All identified patients 
were recalled for a follow-up visit at which details miss-
ing from the medical history that could be relevant for 
ONJ development were gathered (e.g. tobacco use) and a 
detailed examination of the oral cavity was performed.
The following variables were analyzed: sex, age, type of 
bisphosphonate, duration of treatment, comorbid con-
ditions and coadjuvant medication, smoking, previous 
dental procedures, clinical presentation, site affected, 
size and clinical stage of the lesions (5). Informed con-
sent was obtained from all patients who participated in 
the study. The study was reviewed by the Institutional 
Review Board (Galician Health Service �SERGAS�), but 
because of its retrospective nature it was exempt from 
formal approval.
Results
Demographic and clinical characteristics of patients with 
oral bisphosphonates related osteonecrosis of the jaws is 
shown in (Table1). Twenty caucasian patients (19 women 
and 1 man) were identified with a total of 24 lesions that 
satisfied the inclusion criteria. All patients but 2 were born 
in Galicia (the remaining 2 patients lived in this area for 
more than 20 years). Seventeen patients were taking oral 
bisphosphonates for the treatment of osteoporosis and 3 
for the prevention of osteoporosis secondary to glucocor-
ticoid therapy for rheumatoid arthritis. The mean age was 
71.2±7.5 years (range, 53-82 years). The oral bisphospho-
nates administered were alendronate (1� patients, 80%) and 
ibandronate (4 patients, 20%). The mean interval between 
the initiation of treatment and confirmation of a diagnosis 
of ONJ was 66±43 months (range, 6-132 months; median, 
55 months). In 7 (35%) patients the interval was less than 
3� months. �ith regard to concomitant diseases and medi-
cation, 13 (�5%) patients were hypertensive, 4 (20%) were 
diabetic, and 7 (35%) were taking corticosteroids. 
A history of oral surgery in the 12 months prior to the 
appearance of the lesions of osteonecrosis was detected 
in 13 (�5%) patients. Eleven of those patients had under-
gone tooth extractions and 2 had endosseous implants 
placed during treatment with oral bisphosphonates. The 
remaining 7 (35%) patients had not undergone surgical 
dental procedures in the 12 months prior to the diagnosis 
of ONJ, although all had removable dental prostheses. 
Three (15%) patients presented more than 1 ONJ lesion 
at the time of diagnosis: 2 lesions in 2 patients and 3 le-
sions in 1 patient. The majority of lesions (�2,5%) were 
in the mandible, particularly affecting the region of the 
molars and premolars. The most common signs and 
symptoms were bone exposure, pain, suppuration, and 
inflammation (Table 1). 
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Orosinusal communication and sinustis were observed 
in 1 patient, and the presence of an extraoral fistula 
in another; these 2 lesions (8.3% of all the lesions ob-
served) were classified as stage 3. The majority of the 
lesions (18/24 [75%]) were classified as stage 2, with 
exposure of necrotic bone and pain and/or signs of in-
fection. Two lesions were classified as stage 1, with ex-
posure of necrotic bone without pain or signs of infec-
tion. The 2 remaining lesions were classified as stage 0, 
without bone exposure but with nonspecific signs and 
symptoms of ONJ.
Discussion
Although the description of bisphosphonate-related 
ONJ is relatively recent (8), the condition has become 
important in the field of dentistry due to the increased 
number of reported cases and the difficulty of its thera-
peutic management, even in patients treated with oral 
bisphosphonates (�). In a open PubMed-based search 
(until April 2011) we found 14 case series with at least 
10 patients with oral bisphosphonate-related ONJ; add-
ed to the present series, we thus found a total of 310 
patients (6,9,21) (Table 2). The first European series of 
ONJ was published in Spain by Bagán et al. (22) and de-
scribed 10 oncology patients with ONJ after treatment 
with intravenous bisphosphonates. The present study 
describes the clinical presentation and risk factors in 
a series of nononcology patients with ONJ related to 
treatment with oral bisphosphonates. After reviewing 
the literature, we believe that this is the largest case se-
ries described in Spain, and it s´ among the top-ten of the 
largest case series published worldwide including oral 
bisphosphonate-related osteonecrosis patients detected 
in a single city or a delimited geographical region. The 
main limitation of this study is that no information was 
gathered regarding the treatment of the lesions and their 
clinical course; our data do not therefore contribute to 
this area of clinical relevance. Other important bias is 
that clinical characteristics of patients treated in other 
outpatient institutions or by other specialists in this geo-
graphical area, remain unknown. Moreover, as clinical 
stage 0 was defined in 2009 directives and the cases 
were collected from May 2008, stage 0 patients may 
be underestimated. One of the strengths of the study is 
that it was carried out in a limited geographical area, 
reducing the possibility of selection bias and reducing 
the potential influence of ethnic, social, cultural and ge-
netic factors. 
As in other studies, alendronate was the drug most 
commonly used for the treatment of osteoporosis in 
our patients. It is estimated that the incidence of ONJ 
in patients treated with oral bisphosphonates is approxi-
mately 0.7 cases per 100000 population per year (23), 
although some authors consider the true figure to be 
higher, and it has been suggested that the increase in the 
long-term use of this medication will lead to a rise in the 
incidence of ONJ. 
One of the main risk factors for the onset of oral bi-
sphosphonate-related ONJ discussed in the literature 
is the duration of treatment. In a review of the series 
published up to the year 2009, it was stated that the 
mean duration of treatment with oral bisphosphonates 
prior to the appearance of lesions of ONJ was 4.� years 
(24). In our series, the mean time to presentation was 
slightly longer than the figure reported in the literature, 
although it was within the ranges observed. However, 
a considerable number of patients (35%) in our series 
developed ONJ after less than 3 years of treatment with 
oral bisphosphonates, a situation that has already been 
described in the literature (25). The onset of ONJ thus 
appears to be determined not only by the duration of 
the treatment but also by other risk factors, which may 
include local injury, systemic diseases, concomitant 
medication, and genetic predisposition. Twelve (�8%) 
of the 19 women included in our series had systemic 
hypertension and were receiving antihypertensive med-
ication; this percentage is higher than that of Spanish 
women with hypertension in the general population 
in the age range �5 to 74 years (55%). However, this 
could be due to the combined influence of osteoporosis 
and hypertension, based on common pathophysiologic 
mechanisms, as the changes in hormone metabolism as-
sociated with the menopause may be implicated in the 
development of both conditions (2�). Another possible 
risk factor for ONJ is diabetes, particularly in oncology 
patients treated with intravenous bisphosphonates (27). 
In the present series we found that 20% of patients had 
diabetes, a higher prevalence than in the adult popu-
lation from the rest of Spain (10-15%) (28). However, 
taking into account that diabetes is a risk factor for os-
teoporosis (29), that the frequency of diabetic patients 
in other series is lower, the retrospective nature of the 
present study, and the limited number of cases, the im-
portance of diabetes as a risk factor for ONJ in patients 
treated with oral bisphosphonates will need to be con-
firmed in future studies.
Although there is no scientifically demonstrated link 
between bisphosphonate-related ONJ and rheumatoid 
arthritis, a number of hypotheses have recently been 
proposed that suggest that rheumatoid arthritis could 
be a risk factor for bisphosphonate-related ONJ. The 
mechanisms that have been discussed as possible links 
between these disorders include the actions of certain 
inflammatory mediators and the effects of drugs com-
monly used in the treatment of rheumatoid arthritis, par-
ticularly the steroids and methotrexate (MTX), which 
appear to play a relevant role in the onset of bisphos-
phonate-related ONJ (30). The drug group most com-
monly discussed in the literature are the corticosteroids. 
Experimental studies in rats (31) have shown that the 
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combined administration of bisphosphonates and corti-
costeroids produces changes in the hard and soft tissues 
that are similar to those found in patients who develop 
oral lesions of bisphosphonate-related ONJ. Recently, 
Chiu et al. (19) published a series of 12 patients with 
clinicopathologically proved oral bisphosphonate-re-
lated ONJ; all the patients were concurrently adminis-
tered long-term corticosteroids; in these patientes ONJ 
lesions were severe and treatment outcome was unpre-
dictable.In our series, a total of 7 patients were receiv-
ing corticosteroids, 3 of whom had been diagnosed with 
rheumatoid arthritis.
Yarom et al. (20) suggested a possible relationship be-
tween ONJ and smoking. All patients in their series 
were smokers. In contrast, in a later study, Favia et al. 
(13) presented a series of 24 nonsmokers with ONJ re-
lated to oral bisphosphonates; our results are consistent 
with that report, as only 2 of our patients were smokers 
and 1 an ex-smoker. Although there have been reports 
of spontaneous ONJ, those cases are usually associated 
with local injury, almost always related to oral surgery, 
particularly to tooth extractions and the insertion of 
dental implants (19). It has been shown that bisphos-
phonates alter osteoclast function, leading to a delay 
in the initial phase of healing of the socket after tooth 
extraction; this could favor secondary infection and the 
onset of ONJ (32). In our series, we found a considerable 
number of cases, higher than in other series (13,15,18,20) 
in which the onset of ONJ was not associated with pre-
vious surgical dental procedures. Bisphosphonates have 
recently been shown to have an inhibitory effect on the 
proliferation of keratinocytes in the oral mucosa (33), 
and it has been suggested that poorly fitting removable 
dental prostheses could injure the underlying mucosa, 
increasing the risk of developing ONJ in the affected 
bone (34).
The clinical presentation of ONJ in our patients, with 
regard both to the site and to the clinical stage of the le-
sions, was similar to that reported in other studies. The 
predilection for posterior areas of the mandible has also 
been described in other series, as has the predominance 
of patients with stage 2 disease (exposure of necrotic 
bone with pain and/or signs of infection) (10-13, 18).
The oral bisphosphonates are the most widely used 
drugs for the management of osteoporosis, with millions 
of users worldwide. In Spain, these drugs are among 
the top 10 therapeutic subgroups in terms of number of 
prescriptions and health-related costs in the Spanish na-
tional health system. As a result, it may be predicted that 
the number of cases of oral bisphosphonate-related ONJ 
will increase in the coming years, and there is an urgent 
need to substantiate epidemiological characteristics in 
large cohorts of individuals (�). The management of es-
tablished ONJ lesions is complex and the clinical course 
is difficult to predict; prevention and the control of risk Ba
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factors is thus very important. In consequence, one of 
the first strategic initiatives to prevent oral bisphospho-
nate-related ONJ in patients with osteoporosis should 
consist of ensuring the appropriate prescription of these 
drugs and, taking into account that this population has 
considerable requirements for dental treatment (includ-
ing tooth extractions) (35), protocols for oral healthcare 
should be set in motion before starting treatment with 
an oral bisphosphonate. 
In conclusion, in the present series, ONJ induced by oral 
bisphosphonates typically develops in women around 
70 years of age, taking alendronate for 4.5 years, that 
underwent oral surgery in the 12 months prior. Most 
lesions are located in the posterior mandible and are 
classified as stage 2 at diagnosis. Although specific risk 
factors have been described, they are not detected in all 
patients, which lead us to speculate that there may be 
other, as yet unidentified risk factors. There are well-
defined patterns of clinical presentation that can facili-
tate early diagnosis of ONJ. 
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